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Abstract 18 
The survival rate for patients with ovarian cancer has changed little in the past three decades 19 
since the introduction of platinum-based chemotherapy and new drugs are needed. Statins are 20 
drugs used for the treatment and prevention of cardiovascular diseases. Recent work from our 21 
laboratory has shown that pitavastatin has potential as a treatment for ovarian cancer if dietary 22 
geranylgeraniol is controlled. However, relatively high doses of statins are required to induce 23 
apoptosis in cancer cells, increasing the risk of myopathy, the most common adverse effect 24 
associated with statins. This makes it desirable to identify drugs which reduce the dose of 25 
pitavastatin necessary to treat cancer. A drug-repositioning strategy was employed to identify 26 
suitable candidates. Screening a custom library of 100 off-patent drugs for synergistic activity 27 
with pitavastatin identified prednisolone as the most prominent hit. Prednisolone potentiated 28 
the activity of pitavastatin in several assays measuring the growth, survival or apoptosis in 29 
several ovarian cancer cells lines. Prednisolone, alone or in some cases in combination with 30 
pitavastatin, reduced the expression of genes encoding enzymes in the mevalonate pathway, 31 
providing a mechanistic explanation for the synergy.  32 
 33 
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Introduction  34 
Ovarian cancer is a group of heterogeneous diseases which share the same anatomical 35 
location1. It is the most lethal gynaecological cancer, causing the deaths of more than 4000 36 
patients annually in the UK2, 3. Generally, ovarian cancer treatment includes surgery to reduce 37 
the tumour mass and chemotherapy, which is most often carboplatin and paclitaxel4. Despite 38 
considerable improvements in the prognosis of patients with several other solid tumours, 39 
ovarian cancer survival rates have changed little in the past three decades since the introduction 40 
of platinum-based chemotherapy. The development of resistance to chemotherapy plays a key 41 
role in limiting long-term patient survival.  The recent introduction of PARP inhibitors offers 42 
cause for considerable optimism, although these drugs show less activity in patients with a 43 
functional homologous recombination pathway5. Therefore, new therapeutic strategies are 44 
needed for the treatment of ovarian cancer, and especially for advanced and drug-resistant 45 
disease6.  46 
Statins are drugs used to treat elevated cholesterol. Their widespread use in this setting has 47 
allowed the generation of epidemiological evidence which suggests that their use is also 48 
associated with reduced cancer mortality7. Statins inhibit hydroxymethylglutarate Coenzyme 49 
A reductase (HMGCR), the rate limiting step in the mevalonate pathway. This pathway leads 50 
not only to the production of cholesterol, but also isoprenoids which are used to anchor Ras 51 
family GTPases to cell membranes. Statins trigger apoptosis in several types of cancer cells 8. 52 
Recently, published data from our laboratory showed that pitavastatin has promising anti-53 
tumour activity against ovarian cancer xenografts9. However, prospective clinical trials of 54 
statins in cancer have largely been unsuccessful. We have identified three reasons likely to 55 
explain this lack of clinical activity (reviewed in 10). Firstly, the dose of statins used in many 56 
trials were comparable to those used to treat hypercholesterolaemia, yet the statin concentration 57 
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achieved in plasma following such doses falls well below that required to induce apoptosis in 58 
cancer cells in vitro11. Secondly, many of the statins have a relatively short half-life, and once-59 
daily dosing is inadequate to maintain the continual inhibition of HMGCR that we have shown 60 
to be necessary to induce apoptosis12, 13. The choice of statin tested in clinical trials has been, 61 
in our opinion, uniformly inappropriate10. Hydrophilic statins are less potent in a cancer setting, 62 
while lipophilic statins are the most potent anti-cancer agents12 but they are generally 63 
associated with short metabolic half-lives13. Pitavastatin is the only lipophilic statin with an 64 
adequate half-life to maintain continual inhibition of HMGCR using a practical dosing 65 
schedule. Consequently, we consider that high doses of pitavastatin, administered twice daily, 66 
are the most likely to succeed. Lastly, dietary sources of geranylgeraniol can interfere with the 67 
anti-tumour activity of pitavastatin, suggesting diet should be controlled during therapy9. These 68 
observations suggest clinical trials of pitavastatin are warranted. 69 
The use of statins at a high dose and with continuous exposure, as we propose, brings with it 70 
an increased risk of myopathy, the most common adverse effect associated with statin use. In 71 
some rare cases this can lead to rhabdomyolysis and the incidence of this is likely to increase 72 
if high statin doses are used 14. It is, therefore, desirable to identify compounds which synergize 73 
with the anti-tumour activity of pitavastatin in order to reduce the dose needed and potentially 74 
reduce the incidence of myopathy. Combination therapies are among the most successful forms 75 
of treatment of cancer. Tumours, especially in adults, are associated with multiple mutations 76 
and intratumoral clonal heterogeneity is often observed as a result of several different 77 
pathological mechanisms participating in their evolution15. Thus, drug combinations can be 78 
more successful than single agents 16. Drug combinations can also simultaneously affect 79 
different signalling pathways in individual cancer cells, potentially leading to synergistic 80 
activity. Drug combinations may also reduce the emergence of drug-resistant subpopulations. 81 
Lastly, there is an historical precedent for the use of drug combinations because many 82 
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chemotherapeutic regimens incorporate several different drugs.  Therefore, combining drugs 83 
offers the prospect of obtaining a more sustained clinical response. We, and others, have 84 
already shown that bisphosphonates such as zoledronatate potentiate the activity of statins 11, 85 
17-21 and dipyridamole has been shown to potentiate the activity of atorvastatin 22. 86 
 87 
To identify additional drugs which might be synergistic with pitavastatin, we screened a library 88 
of 100 off-patent clinically approved drugs in combination with pitavastatin using cell growth 89 
assays. This library was designed to allow testing of the drugs at clinically achievable 90 
concentrations23. This library has previously been screened to identify niclosamide, an anti-91 
helminthic drug, as a potential therapy for multiple myeloma as it killed several cell lines at 92 
clinically achievable non-toxic concentrations 23.  In this study, we show that prednisolone 93 
potentiates the activity of pitavastatin against a panel of ovarian cancer cell lines.  94 
  95 
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Material and methods  96 
Compounds 97 
Pitavastatin (Livalo, Adooq), Prednisolone, farnesol, geranylgeraniol and mevalonate 98 
(Sigma-Aldrich) were prepared as 20mM stock solution in DMSO. The custom-made drug 99 
repurposing library (FMC1) was provided by Dr. Farhat Khanim, School of Biosciences, 100 
University of Birmingham and is comprised of off-patent, mainly orally bioavailable drugs, at 101 
a concentration which is a multiple of each drug’s plasma Cmax observed in patients 23. 102 
 103 
Cell culture 104 
A panel of ovarian cancer lines (Cov-318, Cov-362, Ovcar-3, Ovcar-4, Ovsaho) were incubated 105 
in a humidified incubator at 37 °C in 5% CO2  atmosphere. Cell lines were maintained in RMPI-106 
1640 (Ovcar-3, Ovcar-4, Ovsaho) or DMEM (Cov-318 and Cov-362) supplemented with 10% 107 
fetal bovine serum, 2mM L-Glutamine and 50 IU/ml penicillin/streptomycin.. Medium for 108 
Ovcar-3 cells was additionally, supplemented with 0.01 mg/ml bovine insulin and 1 mM 109 
sodium pyruvate. 110 
 111 
Screening the drug library with pitavastatin 112 
Ovcar-4 cells were seeded (5000 cells/well) in a 96-well plate. The next day, cells were exposed 113 
to vehicle (DMSO), pitavastatin (10 µM), a library compound, or a combination of pitavastatin 114 
and a compound from the library. The experimenters were blind to the identity of the drugs 115 
which were each given an anonymized code.  Each drug was tested in triplicate in two 116 
independent experiments. After 72-hours incubation, cells were fixed and relative surviving 117 
cells were estimated by staining with SRB and measuring A570 as described previously 
24. The 118 
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Bliss independence criterion was used to estimate the expected effect of the drug combination 119 
if the drugs interacted additively 25. The “Bliss excess” was calculated from the difference 120 
between the observed effect and expected additive effect.  121 
 122 
Cell growth assays 123 
Human ovarian cancer cells (5000 cells/well) were plated in 96-well plates. The following day, 124 
cells were exposed 18 different concentrations of the drugs for 72-hour, with the exception of 125 
Cov-318 and Cov-362 cells which were incubated for 120-hour because of their slower growth 126 
rate. Cells were stained with sulforhodamine B as previously described 24. IC50 values and Hill 127 
coefficients were determined using Graphpad Prism 6. 128 
To evaluate synergy, complete concentration-response curves for pitavastatin were measured 129 
in the absence or presence of a fixed concentration of prednisolone. Combination indices were 130 
calculated as described 26 at fraction affected = 0.5. Some cells were also exposed to 20 μM 131 
mevalonate, 10 μM farnesol (FOH), or 10 μM geranylgeraniol (GGOH) as indicated.  132 
 133 
Spheroid cultures 134 
GravityTRAP ULA Plates (InSphero) were pre-wet with 40 µl of medium before seeding 500 135 
cells in 70 µl growth medium per well. Following centrifugation (ALC PK120 Centrifuge, 1 136 
min at 900 rpm), the plates were returned to the incubator. After 3-5 days, spheroids were 137 
observed. Thereafter, drugs were added in 30 µL of growth medium. Ovcar-4 or Cov-362 cells 138 
were incubated for 72 or 120 hours, respectively before relative ATP levels were measured by 139 
addition of 25 µL of cell Titer-Glo Luminescent assay reagent (Promega, Madison, WI, USA). 140 
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The effect of the combination was compared to that expected for an additive interaction using 141 
the Bliss independence criterion as described above. 142 
 143 
Caspase-Glo3/7 Assays 144 
For each experiment two 96 well plates containing 5000 cells per well in 80 µl of growth 145 
medium were prepared. After 48 hours, caspase activity was measured in one plate by addition 146 
of 20 µL of Caspase-Glo 3/7 reagent (Promega, Madison, WI, USA). The second plate was 147 
stained with SRB as described above and the caspase activity normalised to the SRB staining.  148 
 149 
Annexin V/ propidium iodide staining  150 
Ovcar-4 or Cov-362 cells were seeded at density of 2×106 cells per well of a 6 well plate in 2 151 
mL of growth medium. The following day, drugs were added in 20 μL of growth medium to 152 
the indicated final concentration. Ovcar-4 and Cov-362 cells were incubated with drugs for 48 153 
and 72 hours, respectively. The cells were labelled using an annexin-V FITC kit (Miltenyi 154 
biotech). Cells were trypsinized, washed in ice-cold PBS and centrifuged at 300 x g for 5 155 
minutes. The pellets were re-suspended in 1 ml of binding buffer, and centrifuged for 10 156 
minutes at 300 x g. The pellets were re-suspended in 100 µl of annexin V binding buffer and 157 
10 µl of annexin V fluorochrome were added to each sample and incubated for 10 minutes in 158 
dark at room temperature. The washing step were repeated with 1 ml of annexin V binding 159 
buffer. Lastly, the cells were re-suspended in 500 µl annexin V Binding Buffer and 5 µl of 160 
propidium iodide (1µg/ml) added before analysis by flow cytometry. The viability of cells was 161 
defined as alive (annexin V-negative and PI-negative), early apoptotic cells (annexin V-162 
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positive and PI-negative), late apoptotic cells or dead cells (annexin V-positive and PI-positive) 163 
and necrotic cells (annexin V-negative and PI-positive). 164 
 165 
Western blotting 166 
Ovcar-4 or Cov-362 cells were seeded at density of 2 × 105 cells per well of a 6 well plate in 2 167 
mL of growth medium. 20 μL of medium containing pitavastatin or prednisolone or a 168 
combination of both were added to the indicated final concentration. After 48-hour (Ovcar-4) 169 
and 96-hour (Cov-362) incubation with drugs, floating and adherent cells were collected. Cell 170 
lysates were prepared as described27 and protein concentration measured by BCA assay. Equal 171 
masses of the sample proteins were separated by SDS-PAGE and transferred to a PVDF 172 
membrane. The membrane was incubated overnight at 4°C with primary antibody:  anti-PARP 173 
(1:1000) (Cell Signaling Technology); anti-HMGCR (1/1000) (Abcam); anti-GGTI-β subunit 174 
(1/1000) (Santa Cruz); anti-RABGGTII-β subunit (1/1000) (Santacruz); anti-MVD (1/1000) 175 
(Abcam), anti-IDI1 (1/2000) (Abcam) anti-HMGCS (1/1000) (Abcam) or with anti-GAPDH 176 
antibody (1:5000) (Millipore) as loading control. Proteins were visualised using peroxidase-177 
conjugated secondary antibodies and Uptilight™ Ultra WB Chemiluminescent Substrate 178 
(Interchim, France). 179 
Statistical analysis 180 
Student’s paired t-test with Welch corrections or one-way ANOVA followed by Tukey’s post 181 
hoc performed for multiple statistical comparisons were performed as indicated. Differences 182 
considered statistically significant at P < 0.05. 183 
  184 
10 
 
Results 185 
Testing a library of compounds in combination with pitavastatin  186 
Ovcar-4 cells, which are considered representative of high grade serous ovarian cancer28, were 187 
used to test the effect in cell growth assays of pitavastatin alone and in combination with 188 
individual compounds from a library (FMC1) of off-patent, licensed drugs23. Six compound 189 
showed significant growth inhibitory activity against Ovcar-4 cells when they were tested as 190 
single agents at a concentration similar to their Cmax achieved in patients. Five compounds 191 
potentiated the effect of pitavastatin, namely prednisolone (71.6 µM, Bliss excess = 0.29), 192 
rifampicin (12.2 µM, Bliss excess = 0.19), praziquantel (3.5µM, Bliss excess = 0.16), flutamide 193 
(6.22µM, Bliss excess = 0.23) and mefenamic acid (41.4µM, Bliss excess = 0.21). Prednisolone 194 
showed the most significant synergistic effect (70 μM, Bliss excess ~ 0.4) and was selected for 195 
further analysis. 196 
 197 
Single agent activity in panel of ovarian cancer cell line. 198 
The single agent activity of prednisolone was determined using a panel of ovarian cancer cells 199 
considered representative of high grade serous ovarian cancer, namely Ovcar-4, Ovcar-3, 200 
Ovsaho, Cov-318 and Cov-362 cells28. Prednisolone, as a single agent, showed weak growth 201 
inhibitory activity in all ovarian cancer cell lines at concentrations up to 500 μM and an 202 
accurate IC50 could not be determined using pharmaceutically-relevant concentrations. This 203 
agrees with other studies that report that corticosteroids have insignificant growth inhibitory 204 
activity against solid tumours29. In contrast, and as we have previously reported 9, 17, 205 
pitavastatin inhibited the growth of tested cell lines with an IC50s ranging from 1.1 to 4.8µM 206 
(Table 1).  207 
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 208 
Pitavastatin combination with prednisolone 209 
To confirm the results of the screen, a range of concentrations of pitavastatin were combined 210 
with a fixed concentration of prednisolone (70µM) and their activity assessed in cell growth 211 
assays. At this concentration, prednisolone has no measureable effect as a single agent, so any 212 
change in the apparent potency of pitavastatin must reflect a drug interaction. Prednisolone 213 
potentiated the activity of pitavastatin against all the ovarian cancer cell lines that were tested 214 
(Ovsaho, Cov-318, Cov-362, Ovcar-3 and Ovcar-4), with significant reduction in pitavastatin 215 
IC50s (Fig. 1A). To confirm this formally, combination indices were calculated. Significant 216 
synergy between prednisolone and pitavastatin was observed in all the cell lines (Fig. 1B).  217 
Effect of mevalonate pathway intermediate metabolites on the combination 218 
We 9, and others (30-32, have previously shown that some mevalonate pathway metabolites 219 
downstream of HMGCR including mevalonate and geranylgeraniol reduce the cytotoxic effect 220 
of statins. To determine if the anti-proliferative activity of the pitavastatin and prednisolone 221 
combination resulted from inhibition of mevalonate pathway, Ovcar-4 and Cov-362 cells were 222 
exposed to the drug combination and further supplemented with mevalonate, farnesol or 223 
geranylgeraniol. The addition of mevalonate to cells significantly reduced the growth 224 
inhibitory activity of drug combination. Furthermore, supplementing the combination with 225 
geranylgeraniol but not farnesol also significantly prevent growth inhibition (Fig. 2). These 226 
results suggested that activity of combination is mediated mainly through inhibition of 227 
mevalonate pathway and most likely through inhibition of geranylgeranylation. 228 
 229 
ATP assay in spheroid cultures  230 
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To recapitulate the 3D architecture of tumours more closely in vitro, Ovcar-4 and Cov-362 231 
spheroids were prepared and the effect of the pitavastatin and prednisolone combination was 232 
evaluated. ATP was measured as a surrogate of surviving cell number. The combination of 233 
prednisolone and pitavastatin reduced ATP significantly more than would have been 234 
anticipated if the drugs acted additively (estimated from the Bliss independence criterion; Fig. 235 
3), thereby confirming a synergistic interaction between the two drugs. 236 
 237 
Prednisolone and pitavastatin synergistically induce apoptosis 238 
When Ovcar-4 cells were treated with solvent or with prednisolone and viewed by phase 239 
contrast microscopy they retained their original morphology. In contrast, cells exposed to 240 
pitavastatin alone detached from the plate surface (Supplementary Figure 1) were round, 241 
shrunken and with blebs and this was more pronounced in cells treated with the drug 242 
combination. To determine if these morphological changes resulted from apoptosis, Ovcar-4 243 
and Cov-362 cell lines were exposed to pitavastatin, prednisolone or the combination of the 244 
two agents before annexin V and propidium iodide staining was measured by flow cytometry. 245 
There were significantly more early apoptotic or late apoptotic dead cells in samples treated 246 
with the drug combination than in cells treated with pitavastatin alone (Figure 4) suggesting 247 
that the drug combination synergistically induced apoptosis. To confirm this, caspase-3/7 248 
activity and PARP cleavage were assessed. Although prednisolone had negligible effect on 249 
caspase 3/7 activity on its own, the combination of pitavastatin with prednisolone caused 250 
significantly more caspase activation than that caused by pitavastatin alone. Consistent with 251 
this, immunoblot analysis demonstrated that the prednisolone and pitavastatin combination caused 252 
significant accumulation of cleaved PARP that was greater than that observed with each single 253 
agent (Figure 5).  254 
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 255 
Identification of a potential mechanism underlying synergy between pitavastatin and 256 
prednisolone.  257 
Prednisolone regulates the expression of genes by binding to the glucocorticoid receptor, a 258 
ligand-dependant transcription factor. This raised the possibility that the synergy between 259 
pitavastatin and prednisolone occurred as a result of prednisolone-induced changes in gene 260 
expression. Previous work33 has identified genes whose expression is altered in 3T3-L cells 261 
exposed to prednisolone, including some which form part of the mevalonate pathway. The 262 
expression of the genes encoding HMGCR, geranylgeranyl transferase I and II (GGTI, GGTII), 263 
isopentenyl diphosphate isomerase (IDI1), mevalonate decarboxylase (MVD) and farnesyl 264 
diphosphate synthase (FDPS) were reported to be decreased in cells exposed to prednisolone. 265 
Consequently, the effect of prednisolone, alone and in combination with pitavastatin, on these 266 
genes products was assessed in ovarian cancer cells. Neither pitavastatin nor prednisolone 267 
when used as single agents notably altered the levels of HMGCR, FDPS, IDI1, MVD, GGTI-268 
β. However, GGTII-β was reduced upon exposure to either pitavastatin or prednisolone as 269 
single agents as well as in cells exposed to the combination of these two drugs.  The 270 
combination of pitavastatin and prednisolone, but not the single agents alone, caused 271 
significant reduction in levels of HMGCR and FDPS (Fig 6).  272 
  273 
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Discussion  274 
Statins in general are well tolerated when used at recommended doses as anti-275 
hypercholesterolemia agent in clinic. However, to cause apoptosis in cancer cells, high doses 276 
are likely to be required, which increases the risk of myopathy, creating a challenge for 277 
redeployment of statins as chemotherapeutic agent. One strategy to potentially minimize the 278 
adverse effects is to identify drugs which synergize with the anti-cancer activity of statins, 279 
thereby reducing the dose of statin required.  Our screen of approved drugs to discover those 280 
which potentiate the activity of pitavastatin identified prednisolone. The synergy between 281 
pitavastatin and prednisolone was confirmed in several assays using a panel of ovarian cancer 282 
cell and led to the decreased expression of mevalonate pathway genes, providing a potential 283 
mechanistic explanation for the synergy. 284 
The synergy between the pitavastatin and prednisolone combination identified in the screen 285 
was verified in several assays. This included cell growth assays in monolayers and in 3D cell 286 
culture. The increase in apparent potency of pitavastatin in the presence of prednisolone, at a 287 
concentration at which itself has minimal effect, provides unequivocal evidence of synergy 288 
between the two drugs. Cell death was mediated, at least in part through, induction of apoptosis. 289 
A synergistic increase in apoptosis was observed in three separate apoptosis assays (Annexin 290 
V labelling, caspase 3/7 activity and PARP cleavage). These observations provides robust 291 
evidence that pitavastatin and prednisolone can interact synergistically. 292 
We have previously shown that pitavastatin causes cell death through inhibition of the 293 
mevalonate pathway even when pitavastatin is used at relatively high concentration 9, 17.  294 
Inhibition of the mevalonate pathway causes disruption of several GTPases which are involved 295 
in cell signalling, regulating cell cycle progression and cell survival34. Consequently, statins 296 
induce apoptosis including an increase in release of mitochondrial cytochrome C to cytosol, 297 
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and activation of caspases 3, 8 and 9 35, 36.  In this study we also found that that the effects of 298 
the combination of prednisolone and pitavastatin was also dependant on inhibition of the 299 
mevalonate pathway, because geranylgeraniol and mevalonate both reduced the activity of the 300 
drug combination. Reminiscent of the effects of statins alone 12, 30-32, farnesol failed to block 301 
the activity of the combination against the cancer cells. This suggests that the effects of the 302 
drug combination are primarily mediated through inhibition HMGCR and the consequent 303 
inhibition of geranylgeranylation. This is also consistent with our previous observation that 304 
inhibition of both GGTI and GGTII potentiates the activity of pitavastatin as a single agent 17.  305 
The foregoing discussion, particularly the effects of geranylgeraniol, strongly argues that the 306 
effect of the combination of pitavastatin and prednisolone depends upon its effects on the 307 
mevalonate pathway. We have also previously shown that that dual inhibition of the 308 
mevalonate pathway, using bisphosphonates to inhibit FDPS, is also synergistic with 309 
pitavastatin17. To explore the mechanism by which prednisolone was synergistic with 310 
pitavastatin in more detail, levels of mevalonate pathway enzymes were investigated by 311 
immunoblotting. An earlier study found that prednisolone altered the expression of genes 312 
encoding several mevalonate pathway enzymes including HMGCR, GGTI, GGTII, IDI1, 313 
MVD and FDPS 33. Inhibiting the mevalonate pathway by two separate mechanisms provides 314 
a potential rationale to explain the synergy we observed between pitavastatin and prednisolone. 315 
We found that the prednisolone-pitavastatin combination cause significant reduction in level 316 
of HMGCR and FDPS enzymes. It was striking that the combination, but not the single agents, 317 
affected the level of these enzymes, consistent with this contributing to the synergy observed 318 
between the drugs. A reduction in GGTII-β was observed following exposure to either of the 319 
drugs as a single agents, as well as in the combination. Taken together, this strongly suggests 320 
that synergy between prednisolone and pitavastatin may result from inhibiting multiple points 321 
on the mevalonate pathway. The effect of related steroids on mevalonate pathway enzymes has 322 
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also been reported by others.  Investigation of the short term effects of dexamethasone in rat 323 
hepatocytes revealed a reduction in cholesterol synthesis37. Dexamethasone also causes down 324 
regulation of HMGCR and FTase enzymes activity in rat AR 4-2J cells 38. Specifically, the 325 
authors found that there is significant reduction in FT-α subunit upon treatment of the cells 326 
with dexamethasone for 48 hours. In contrast, the β-subunit of the enzyme was either 327 
unchanged or slightly reduced. However, it was claimed that even a 50% reduction of FT 328 
activity is not sufficient to prevent Ras isoprenylation and Ras protein were even found to 329 
accumulate during dexamethasone treatment. Therefore, it is plausible that a relatively small 330 
amounts of an active prenyl transferase is sufficient to maintain prenylation process and support 331 
cell survival. We have also previously shown that inhibition of geranylgeranyl transferase I 332 
and II simultaneously is necessary to synergize with pitavastatin 17, suggesting that one 333 
prenyltransferase may compensate for the reduced activity of one of the other enzymes. These 334 
observations suggest that for efficacy in cancer, robust inhibition of the mevalonate pathway 335 
is required and may explain why relatively high concentrations of pitavastatin are required to 336 
induce apoptosis. In turn, this may also further explain why combinatorial inhibition of the 337 
mevalonate pathway potentiates cell death. Although we have shown the combination induces 338 
apoptosis, it is also plausible that the combination affects the autophagy pathway which we12 339 
and others 39 have already shown to be affected by statins. 340 
The most straightforward explanation for the changes in the abundance of mevalonate pathway 341 
enzymes in cells exposed to prednisolone is that their expression is controlled by the 342 
glucocorticoid receptor, a transcription factor to which prednisolone binds. However, the 343 
mevalonate pathway is subject to a complex set of regulatory mechanisms which may provide 344 
an alternative explanation for the activity of prednisolone. Mevalonate pathway enzymes, 345 
particularly HMGCR, are regulated by sterol and non-sterol products of the pathway40. The 346 
HMGCR enzyme itself is regulated at several levels including regulation of its catalytic 347 
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activity, its rate of degradation and its rate of synthesis41. In particular, sterols and oxysterols, 348 
which are product of the mevalonate pathway, play a role in feedback regulation of the 349 
mevalonate pathway. Sterols and oxysterols inhibit transcription of HMGCR and other 350 
mevalonate pathway genes. They bind to the regulatory proteins SCAP and Insig and prevent 351 
the translocation of SREBP to the Golgi complex where it otherwise undergoes activation by 352 
proteolytic cleavage to allow transcription of mevalonate pathway genes42, 43. Oxysterols can 353 
also directly affects the activity of HMGCR, squalene monooxygenase, FDPS and several 354 
enzymes in cholesterol biosynthetic pathway44. Oxysterols also accelerate the degradation of 355 
HMGCR through sterol-sensing domain in a fashion that depends on the mevalonate pathway 356 
regulator Insig40. Therefore, it is reasonable to speculate that prednisolone, which also has a 357 
sterol ring structure, may mimic sterols and oxysterols and binds to some of these sterol 358 
regulatory binding sites. In this manner, prednisolone may reduce the levels of HMGCR and 359 
FDPS enzymes either by decreasing transcription or increasing the degradation of the enzymes, 360 
or a combination of both mechanisms. In this scenario, adding prednisolone to pitavastatin may 361 
prevent reactivation of the mevalonate pathway which would otherwise occur as a result of 362 
reduced cholesterol synthesis following inhibition of HMGCR by pitavastatin. In other words, 363 
maintenance of feedback inhibition by prednisolone provides one explanation for the reduction 364 
in mevalonate pathway enzymes observed in this study. Further work will be necessary to 365 
uncover the detailed basis of the regulation of the mevalonate pathway by prednisolone. 366 
Our previous observations 9, 10, 12, 17 suggest that pitavastatin warrants clinical evaluation in 367 
ovarian cancer. The current work suggests that it may be appropriate to evaluate the 368 
combination of prednisolone and pitavastatin in clinical trials. The concentration of 369 
prednisolone we have used in these studies, although relatively high, is comparable to those 370 
clinically achievable (Cmax) using a relatively high dose of prednisolone 
45. We do not consider, 371 
however, that prednisolone warrants exploration as a single agent in ovarian cancer. Although 372 
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steroids can induce apoptosis in lymphoid cells46 steroids as monotherapy show only limited 373 
activity in breast and prostate cancers but not in other cancer types 47, 48. In agreement, we 374 
found a very limited effect of prednisolone as a single agent on ovarian cancer cell lines. A 375 
further possibility is to consider more complex combinations. We have previously shown 376 
synergy between pitavastatin with bisphosphonates 17  and other workers have also reported 377 
activity of bisphosphonate as single agents against ovarian cancer xenografts in mice 39. Thus 378 
it may be worthwhile considering the clinical use of a combination of pitavastatin with both a 379 
bisphosphonate and with prednisolone. All these drugs are approved for clinical use so there is 380 
no regulatory barrier preventing this in principle. It is also worth considering whether statins 381 
should be combined with chemotherapy. Although some workers have reported mild synergy 382 
between lovastatin and either carboplatin or paclitaxel 39, we previously mostly observed 383 
additivity 12. Furthermore, we observed profound antagonism if cells were exposed to 384 
simvastatin prior to carboplatin 12, possibly reflecting cell cycle arrest reducing the activity of 385 
the chemotherapeutic agents. Thus, we currently do not favour combining pitavastatin with a 386 
chemotherapeutic agent. 387 
  388 
In conclusion, drug repositioning provides a great opportunity to find new indications for 389 
existing drugs. The anti-cancer activity of pitavastatin is potentiated significantly by 390 
prednisolone by augmenting inhibition of the mevalonate pathway. Clinical trials of 391 
prednisolone with pitavastatin in patients with ovarian cancer may be warranted. 392 
 393 
 394 
 395 
 396 
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Figure Legends 408 
 409 
Figure 1 Synergy between pitavastatin and prednisolone in cell growth assays 410 
A. The potency of pitavastatin (IC50 in cell growth assays) in the presence and absence of a  411 
fixed concentration of prednisolone (70µM) against a panel of ovarian cancer cell lines. The 412 
IC50 was significantly increased by inclusion of prednisolone in all the tested cell lines (**, 413 
*** paired t-test, P < 0.01, 0.001, respectively, n=3). B. Combination indices (CI) (Mean ± 414 
SD, n=3-4) were calculated for the above data and are quoted at a fraction affected of 0.5. *, 415 
** differed significantly from unity where indicated (*, ** P ≤ 0.05, 0.01, respectively). 416 
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 417 
Figure 2 Mevalonate pathway intermediates reduce the activity of pitavastatin.  The 418 
addition of geranylgeraniol (10 µM) and mevalonate (20 µM), but not farnesol (10 µM), 419 
suppressed the effect of pitavastatin or the pitavastatin and prednisolone combination.  420 
Ovcar-4 and Cov-362 cell lines were exposed to serial dilution of pitavastatin in combination 421 
with prednisolone (70µM) for 72 and 120 hours, respectively. The data is presented as a 422 
fraction of the top of the curve calculated by curve fitting (mean ± S.D., n = 3). “C” 423 
represents the control cells exposed to solvent alone. 424 
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 425 
Figure 3 The effect of pitavastatin and prednisolone on spheroids. Spheroids of Ovcar-4 426 
and Cov-362 cells were treated with the indicated drug concentration for 72 hours (Ovcar-4) 427 
or 120 hours (Cov-362).  The relative viabilities were then measured using CellTiter-Glo 428 
assay to measure relative ATP and expressed as fraction of that measured in control samples 429 
treated with solvent (mean ± SD; n = 3). The observed effect of the drug combination were 430 
compared to the effect expected if the drugs had additive effects  which was calculated using 431 
the Bliss independence criterion (shown with a line for each drug combination) from the 432 
measured effect of the individual drugs in each individual experiment. The results were 433 
significantly different from the Bliss expected effect where shown (*, P < 0.05; paired t-test). 434 
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 435 
Figure 4. Prednisolone and pitavastatin synergisticially increase staining with annexin V 436 
and propidium iodide.  Ovcar-4 (A) or Cov-362 (C)  cells were exposed to the indicated 437 
drug concentrations for 48 hours, the cells were labelled with annexin V and propidium 438 
iodide and assessed by flow cytometry. The results shown are representative of 3 439 
experiments. (B,D) The percentage of cells in each quadrant  were compared with the control 440 
untreated cells (*) or with pitavastatin alone (#). The results (mean ± S.D., n= 3) were 441 
significantly different were indicated (*,#,P < 0.05; P,**, # # <0.01; ***,###, ### < 0.001) 442 
(ANOVA test followed by Tukey's post hoc test). 443 
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 444 
Figure 5  Prednisolone and pitavastatin synergistically increase Caspase 3/7 activity and 445 
PARP cleavage. Caspase3/7 activity was measured by Caspase 3/7-Glo assay and the results 446 
expressed as fold of control (mean ± SD; N=3). Cells were treated with of pitavastatin (10 447 
μM) andor  prednisolone (10 μM Ovcar-4, 7 μM Cov-362) for 48 hours (Ovcar-4) or 72 448 
hours (Cov-362). (P= **<0.01, *** < 0.001; t-test, n=3).. PARP was measured by 449 
immunoblotting (n=3). 450 
 451 
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 452 
Figure 6 Effect of prednisolone and pitavastatin on mevalonate pathway enzymes. 453 
Ovcar-4 and Cov-362 cell line were exposed for 48 hours or 72 hours, respectively, to 454 
prednisolone (70 μM) and or pitavastatin (10 μM). The level of mevalonate enzymes was 455 
detected by immunoblotting for  HMGCR, GGTI-β, GGTII-β, FDPS, MVD, IDI1 and 456 
GAPDH,(n = 3). 457 
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 458 
Supplementary figure Ovcar-4 cells wre treated with the indicated concentrations of 459 
pitavastatin and/or prednisolone and viewed by phase contrast microscopy. Significantly 460 
fewer cells remained attached in cells treated with the drug combination.   461 
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Table 1 Single agent potency of pitavastatin in cell growth assays. The potency of 462 
pitavastatin was measured in cell growth assays. The IC50 is reported as the mean (±S.D.) of 463 
the indicated number (n) of experiments 464 
Cell lines 
Pitavastatin 
IC50 (µM) 
Number of 
experiments 
Cell line IC50 (μM) n 
Cov-318 3.1 ± 0.6 4 
Cov-362 3.3 ± 0.7 4 
Ovcar-3 4.1 ± 0.1 3 
Ovcar-4 4.8 ± 0.6 3 
Ovsaho 1.1 ± 0.3 4 
  465 
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